In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 576-579

  Glover, Jason M ^a   Loriaux, Marc ^a   Tyner, Jeffrey W ^a   Druker, Brian J ^a   Chang, Bill H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

ALL; Dasatinib; E2A HLF

Indexed keywords

ASPARAGINASE; CLOFARABINE; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CAPILLARY LEAK SYNDROME; CASE REPORT; CHILD; CYTOGENETICS; DRUG TOLERABILITY; FATIGUE; GENE REARRANGEMENT; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; KIDNEY FAILURE; MALE; MULTIPLE ORGAN FAILURE; NEUTROPENIA; PALLOR; PANCYTOPENIA; PRIORITY JOURNAL; SCHOOL CHILD; VOMITING;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 19; HUMANS; LYMPHOCYTES; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TRANSLOCATION, GENETIC;

EID: 84863859105     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23383     Document Type: Article

References (14)

1. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood 1997; 90: 4243-4251.
2. Raimondi SC, Privitera E, Williams DL, et al. New recurring chromosomal translocations in childhood acute lymphoblastic leukemia. Blood 1991; 77: 2016-2022.
3. Dang J, Inukai T, Kurosawa H, et al. The E2A-HLF oncoprotein activates Groucho-related genes and suppresses Runx1. Mol Cell Biol 2001; 21: 5935-5945.
4. Hunger SP, Ohyashiki K, Toyama K, et al. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev 1992; 6: 1608-1620.
5. Inukai T, Hirose K, Inaba T, et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007; 21: 288-296.
6. Yeung J, Kempski H, Neat M, et al. Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients' cells. Haematologica 2006; 91: 422-424.
7. Minson K, Vear S, Prasad P, et al. The prognostic significance of t(17;19) on outcome of children with pre-B acute lymphoblastic leukemia (ALL). In: Arececi R, editor. American society of pediatric hematology/oncology, Vol. 56. Baltimore, MD: Wiley-Blackwell; 2011. p. 927.
8. Baudis M, Prima V, Tung YH, et al. ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. Pediatr Blood Cancer 2006; 47: 757-764.
9. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27: 5175-5181.
10. Hu Y, Liu Y, Pelletier S. Requirement of Src kinases Lyn, Hck, and Fgr for BCR-ABL 1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453-461.
11. Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996; 87: 1211-1224.
12. Veldurthy A, Patz M, Hagist S, et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008; 112: 1443-1452.
13. Guo B, Blair D, Chiles TC, et al. Cutting Edge: B cell receptor (BCR) cross-talk: the IL-4-induced alternate pathway for BCR signaling operates in parallel with the classical pathway, is sensitive to Rottlerin, and depends on Lyn. J Immunol 2007; 178: 4726-4730.
14. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010; 116: 2070-2077.